FAVORABLE RESULTS REPORTED BY CYTRX FOR HIV VACCINE
CytRx has announced interim results from a Phase I clinical trial indicating that a novel HIV DNA + protein vaccine was well tolerated, stimulated immune T-cells that potentially can attack AIDS virus-infected cells, and produced potent antibody responses with neutralizing activity against multiple HIV viral strains.
The results were presented at the AIDS Vaccine 2005 International Conference in Montreal. The HIV vaccine formulation DP6-001 was created by researchers at the University of Massachusetts Medical School and Advanced BioScience Laboratories, and was funded by a five-year HIV Vaccine Design and Development Team contract from the National Institute of Allergy and Infectious Diseases, part of the NIH.
The goal of the trial is to assess the ability of the DP6-001 vaccine to safely stimulate both antibody and T-cell immune responses to viral protein antigens in the vaccine, including "envelope," which is also carried by HIV. The envelope antigen is a critical protein on the surface of the AIDS virus that facilitates the infection of humans.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May